These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36413741)

  • 1. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.
    Dzimitrowicz HE; Wilson LE; Jackson BE; Spees LP; Baggett CD; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman MS; Gross CP; Dinan MA; Wheeler SB
    JCO Oncol Pract; 2023 Feb; 19(2):e213-e227. PubMed ID: 36413741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.
    Kaye DR; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Pollack CE; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB; Dinan MA
    J Geriatr Oncol; 2022 Jun; 13(5):614-623. PubMed ID: 35125336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
    Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
    Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
    Pritchard JE; Wilson LE; Miller SM; Greiner MA; Cohen HJ; Kaye DR; Zhang T; Dinan MA
    J Am Geriatr Soc; 2022 Aug; 70(8):2330-2343. PubMed ID: 35499667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
    Spees LP; Wheeler SB; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman M; Gross CP; Dinan MA
    Cancer Med; 2021 Oct; 10(19):6653-6665. PubMed ID: 34480518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.
    Spees LP; Dinan MA; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George DJ; Scales CD; Pritchard JE; Leapman M; Gross CP; Wheeler SB
    Clin Genitourin Cancer; 2022 Oct; 20(5):e396-e405. PubMed ID: 35595633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive end-of-life care across gradients of cognitive impairment in nursing home patients with metastatic cancer.
    Koroukian SM; Douglas SL; Vu L; Fein HL; Gairola R; Warner DF; Schiltz NK; Cullen J; Owusu C; Sajatovic M; Rose J
    J Am Geriatr Soc; 2023 Nov; 71(11):3546-3553. PubMed ID: 37515440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Aggressive End-of-Life Care Among Older Adults With Metastatic Cancer Living in Nursing Homes and Community Settings.
    Koroukian SM; Douglas SL; Vu L; Fein HL; Gairola R; Warner DF; Schiltz NK; Cullen J; Owusu C; Sajatovic M; Rose J
    JAMA Netw Open; 2023 Feb; 6(2):e230394. PubMed ID: 36811860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations Between Health Literacy and End-of-Life Care Intensity Among Medicare Beneficiaries.
    Luo Q; Shi K; Hung P; Wang SY
    Am J Hosp Palliat Care; 2021 Jun; 38(6):626-633. PubMed ID: 33472379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy.
    Forman R; Long JB; Westvold SJ; Agnish K; Mcmanus HD; Leapman MS; Hurwitz ME; Spees LP; Wheeler SB; Gross CP; Dinan MA
    JNCI Cancer Spectr; 2024 Sep; 8(5):. PubMed ID: 39133171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the use of aggressive end-of life care among frail and non-frail patients with cancer using a claims-based frailty index.
    Sachdev R; Shearn-Nance G; Vu L; Bensken WP; Douglas SL; Koroukian SM; Rose J
    J Geriatr Oncol; 2024 Mar; 15(2):101706. PubMed ID: 38320468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End-of-life care quality outcomes among Medicare beneficiaries with hematologic malignancies.
    Egan PC; LeBlanc TW; Olszewski AJ
    Blood Adv; 2020 Aug; 4(15):3606-3614. PubMed ID: 32766855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Advance Care Planning Visits With Intensity of Health Care for Medicare Beneficiaries With Serious Illness at the End of Life.
    Weissman JS; Reich AJ; Prigerson HG; Gazarian P; Tjia J; Kim D; Rodgers P; Manful A
    JAMA Health Forum; 2021 Jul; 2(7):e211829. PubMed ID: 35977213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
    Wheeler SB; Spees LP; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Dinan MA
    JCO Oncol Pract; 2021 Dec; 17(12):e1895-e1904. PubMed ID: 34138665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.
    Wilson LE; Spees L; Pritchard J; Greiner MA; Scales CD; Baggett CD; Kaye D; George DJ; Zhang T; Wheeler SB; Dinan MA
    Kidney Cancer; 2021; 5(3):115-127. PubMed ID: 34632169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Home Health for Community-Dwelling Older Adults Near the End of Life: A Resource Beyond Hospice?
    Oh A; Hunt LJ; Ritchie CS; Ornstein KA; Kelley AS; Rajagopalan S; Ankuda CK
    J Palliat Med; 2023 Mar; 26(3):385-392. PubMed ID: 36137095
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of high-intensity care at the end of life among older adults with solid tumors: A population-based study.
    Baird CE; Wulff-Burchfield E; Egan PC; Hugar LA; Vyas A; Trikalinos NA; Liu MA; Bélanger E; Olszewski AJ; Bantis LE; Panagiotou OA
    J Geriatr Oncol; 2024 Jun; 15(5):101774. PubMed ID: 38676975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Billed Advance Care Planning with End-of-Life Care Intensity for 2017 Medicare Decedents.
    Gupta A; Jin G; Reich A; Prigerson HG; Ladin K; Kim D; Ashana DC; Cooper Z; Halpern SD; Weissman JS
    J Am Geriatr Soc; 2020 Sep; 68(9):1947-1953. PubMed ID: 32853429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Contribution of Patient-Provider Communication and Cancer Diagnosis to Racial Disparities in End-of-Life Care Among Medicare Beneficiaries.
    Samuel-Ryals CA; Mbah OM; Hinton SP; Cross SH; Reeve BB; Dusetzina SB
    J Gen Intern Med; 2021 Nov; 36(11):3311-3320. PubMed ID: 33963508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between survival time with metastatic breast cancer and aggressive end-of-life care.
    Accordino MK; Wright JD; Vasan S; Neugut AI; Gross T; Hillyer GC; Hershman DL
    Breast Cancer Res Treat; 2017 Nov; 166(2):549-558. PubMed ID: 28752188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.